HBM Healthcare Investments AG / Key word(s): Half Year Results HBM Healthcare Investments achieved a positive performance in the first half of the 2024/2025 financial year. The net asset value per share (NAV) increased by 1.5 per cent to CHF 244.34. The share price rose by 1.7 per cent to CHF 189.40. Based on the reported NAV, the company expects a half-year profit of around CHF 23 million (previous year: loss of CHF 70 million). Private companies (sale of Yellow Jersey Therapeutics to Johnson & Johnson, revaluation of Swixx Biopharma and impairment losses on various investments) and listed companies contributed equally to the increase in value. Negative currency effects reduced performance by just under 5 per cent. These figures are the preliminary result based on the current state of the closing process. The final result will be published with the half-year report on 21 October 2024. Contact End of Inside Information |
Language: | English |
Company: | HBM Healthcare Investments AG |
Bundesplatz 1 | |
6300 Zug | |
Switzerland | |
Phone: | +41438887171 |
Fax: | +41438887172 |
E-mail: | info@hbmhealthcare.com |
Internet: | https://www.hbmhealthcare.com |
ISIN: | CH0012627250 |
Valor: | 1262725 |
Listed: | SIX Swiss Exchange |
EQS News ID: | 1999967 |
End of Announcement | EQS News Service |
|
1999967 01-Oct-2024 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.